GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: TD-1607 is from a series of glycopeptide-cephalosporin heterodimer antibacterial compounds, disclosed in a 2005 patent [2] and designed to treat serious infections caused by Gram-positive bacteria.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Butler MS, Paterson DL. (2020)
Antibiotics in the clinical pipeline in October 2019. J Antibiot (Tokyo), 73 (6): 329-364. [PMID:32152527] |
|
2. Fatheree PR, Linsell MS, Marquess D, Trapp SG, Moran EJ, Aggen JB. (2005)
Cross-linked glycopeptide-cephalosporin antibiotics. Patent number: WO2005005436A2. Assignee: Innoviva Inc. Priority date: 09/07/2004. Publication date: 20/01/2005. |
|
3. Surur AS, Sun D. (2021)
Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates. Front Chem, 9: 659845. [PMID:33996753] |